Venture financing for mRNA-based vaccines declines 82% in 2025 YTD
Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m in the 2025's…
Analyst Comment
Trump administration announces MFN drug pricing deal with Pfizer
Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights
ERS 2025: Long-term CFTR use shows clinical benefit but variable microbial impact
ERS 2025: APG808 to address need for biologic for moderate asthma
First responders see AI and other advanced tech as essential
Expanding GLP-1 horizons: Novo Nordisk leads MASH therapeutic race
FDA gives first approval for recurrent respiratory papillomatosis therapy
